Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis.
about
Cardiovascular comorbidity in rheumatic diseases: a focus on heart failureIs nephrolithiasis an unrecognized extra-articular manifestation in ankylosing spondylitis? A prospective population-based Swedish national cohort study with matched general population comparator subjectsLong-term frequent use of non-steroidal anti-inflammatory drugs might protect patients with ankylosing spondylitis from cardiovascular diseases: a nationwide case-control studyDiagnostic Prevalence of Ankylosing Spondylitis Using Computerized Health Care Data, 1996 to 2009: Underrecognition in a US Health Care SettingAre ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study.The genetic basis of ankylosing spondylitis: new insights into disease pathogenesisThe risk for depression in patients with ankylosing spondylitis: a population-based cohort study.Efficacy of high intensity exercise on disease activity and cardiovascular risk in active axial spondyloarthritis: a randomized controlled pilot studyIncreased risk of ischemic heart disease in young patients with newly diagnosed ankylosing spondylitis--a population-based longitudinal follow-up study.Increased risk of ischemic stroke in young patients with ankylosing spondylitis: a population-based longitudinal follow-up study.Risk of coronary artery disease in patients with ankylosing spondylitis: a systematic review and meta-analysis.Cardiovascular risk management in patients with active ankylosing spondylitis: a detailed evaluation.Management and evaluation of extra-articular manifestations in spondyloarthritisRegional radiographic damage and functional limitations in patients with ankylosing spondylitis: differences in early and late disease.Cardiorespiratory fitness and cardiovascular risk in patients with ankylosing spondylitis: a cross-sectional comparative studyUpdate on juvenile spondyloarthritis.Cardiovascular and cerebrovascular diseases in ankylosing spondylitis: current insights.Cardiovascular risk in the rheumatic disease patient undergoing orthopedic surgery.Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis?Axial spondyloarthritis: the heart of the matter.Quantitative metagenomics reveals unique gut microbiome biomarkers in ankylosing spondylitis.Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative.Higher risk of incident ankylosing spondylitis in patients with uveitis: a secondary cohort analysis of a nationwide, population-based health claims database.Secular trends in sickness absence among Swedish patients with ankylosing spondylitis and psoriatic arthritis.Radiographic progression is associated with increased cardiovascular risk in patients with axial spondyloarthritis.Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study.Prevalence of cardiovascular-related comorbidity in ankylosing spondylitis, psoriatic arthritis and psoriasis in primary care: a matched retrospective cohort study.Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis?Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study.Adalimumab and Non-Arteritic Anterior Ischaemic Optic Neuropathy: A Case ReportAssessment of SpondyloArthritis International Society criteria for axial spondyloarthritis in chronic back pain patients with a high prevalence of HLA-B27.Modifiable cardiovascular risk factors in patients with ankylosing spondylitis.NT-proBNP levels may be influenced by inflammation in active ankylosing spondylitis receiving TNF blockers: a pilot study.Differences in physical activity patterns in patients with spondylarthritis.Serum levels of novel noggin and sclerostin-immune complexes are elevated in ankylosing spondylitis.Patterns of comorbidity and disease characteristics among patients with ankylosing spondylitis-a cross-sectional study.Clinical characteristics and medical management of Iranian patients with ankylosing spondylitis.Decreased physical activity and cardiorespiratory fitness in adults with ankylosing spondylitis: a cross-sectional controlled study.Centre-related variability in hospital admissions of patients with spondyloarthritis.Comorbidity, disability, and healthcare expenditure of ankylosing spondylitis in Korea: A population-based study.
P2860
Q26823443-93AC3952-B68E-4146-8CF5-8A118B24384EQ28545171-9F397E1B-4BB5-452F-9551-B66049A1AFFBQ28547208-A1064FEF-C6B3-4E2A-A888-45F2C762AD13Q31118921-50F6DE91-62B1-4240-8ECF-5B701D2F8F44Q33706485-24640D57-6CB8-48C0-8CFB-F3FDF830961FQ33806334-3BDD94A5-8C3B-417E-BC70-CED4B61282EEQ34267367-0FBFEFB1-DA78-40C1-AD84-B69040736E95Q34277511-A654D513-F906-4123-AF3F-5D5EEB686C22Q34731291-1F5BFED6-91C0-4FCB-A3ED-3584573227BFQ35142805-CD7860DF-887D-4343-8C12-CEA2E2149A92Q35238112-71280499-0E4E-47E4-AA39-2DA3953AA631Q35496549-5A90F3EC-DBCD-4537-8969-B366A78A7634Q36439889-1AE0D119-B3F6-422D-AA4F-B86519A327D6Q36522063-1F16EC89-082B-4BEF-9C2F-5A9B0810C275Q36746588-13AD7BA6-A468-4AA3-9622-3B0271FF8147Q37598921-CC31F12E-7479-4889-9F90-C392158CED65Q38025994-3987BDF2-9C0E-4CC1-97B3-8088764A7787Q38124279-972A89BF-2A07-4012-85B2-C7D3FC63AB97Q38185646-C0E57788-8A99-47B7-920F-627A05C7F410Q38469239-91AC223E-E32F-4C70-B902-9C2E38688723Q38657093-87D35A40-0178-46A3-B685-21D947570E90Q38777496-EF475F4E-0F04-42A7-A903-80AE61021152Q38796474-71AFCEF3-F36D-4AC1-93BA-72AA4AD117FCQ40054277-EB2F9E3D-3A94-428A-B432-D1540DC1B9B1Q40324538-E36D22FA-0035-4683-AFAA-9471CD984E47Q40405924-0815D31B-EC9C-430F-9362-698AA3312B98Q40638928-A91815A9-4508-40A5-8261-1DFC70C65655Q40709084-E3E2A906-65E6-4C54-9D03-1B0DDEB13657Q41523582-11DBFCF2-09FF-4C91-B212-957E142FFE32Q42363512-F3D4C3C3-E8EB-4A29-8077-5662DEF103DFQ43759230-7864EC0F-3E04-4742-8DD8-9333B9EDF411Q43986221-367AA0DF-10C4-44E1-8233-95E236749B5EQ44729046-915F7E1A-F803-472F-8BAC-4C17EBD60837Q45269344-19004359-317E-4706-BE8C-00CF0C1E2F34Q46379699-8D00DCE1-3ECA-4025-9EF5-BEC498D646C5Q47627994-2FB40AD3-4935-460B-A8D6-A4F83E89C5C7Q48132281-3EB9AC84-A29D-493A-A1CF-8FD2E4497DD8Q48148670-6E980171-DB69-4201-977A-C0D2BF850F4FQ48177339-BE2D93D5-1A18-4C84-91B1-D702F5ABDA91Q50114438-AE9057DF-8148-4DF8-8F2E-5431AFDCD41D
P2860
Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Population-based estimates of ...... ase in ankylosing spondylitis.
@en
Population-based estimates of ...... ase in ankylosing spondylitis.
@nl
type
label
Population-based estimates of ...... ase in ankylosing spondylitis.
@en
Population-based estimates of ...... ase in ankylosing spondylitis.
@nl
prefLabel
Population-based estimates of ...... ase in ankylosing spondylitis.
@en
Population-based estimates of ...... ase in ankylosing spondylitis.
@nl
P50
P356
P1476
Population-based estimates of ...... ase in ankylosing spondylitis.
@en
P2093
Ingemar F Petersson
P304
P356
10.1002/ACR.20408
P577
2011-04-01T00:00:00Z